Hematologic malignancies: newer strategies to counter the BCL-2 protein

Reduction in platelet counts as a mechanistic biomarker and guide for adaptive dose-escalation in phase I studies of the Bcl-2 family inhibitor ABT-263

(2017) A. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Antisense oligonucleotides in therapy for neurodegenerative disorders

(2015) Melvin M. Evers et al.   ADVANCED DRUG DELIVERY REVIEWS

Targeted antisense radiotherapy and dose fractionation using a 177Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate

(2015) Dijie Liu et al.   NUCLEAR MEDICINE AND BIOLOGY

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

(2014) Wendi V. Rodrigueza et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

(2014) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Antisense oligonucleotides in cancer

(2014) Daniela Castanotto et al.   CURRENT OPINION IN ONCOLOGY

Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms

(2014) Timothy A. Vickers et al.   PLoS One

Antisense therapeutics in oncology: current status

(2014) Ammad Ahmad Farooqi et al.   OncoTargets and Therapy

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

(2013) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance

(2013) Steve A Maxwell et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Apoptosis Regulation at the Mitochondrial Outer Membrane

(2013) Laura A. Gillies et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

(2013) M Scherr et al.   LEUKEMIA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Low-Intensity Therapy in Adults with Burkitt's Lymphoma

(2013) Kieron Dunleavy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

(2012) Y. Oki et al.   BLOOD

BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

(2012) Victoria Del Gaizo Moore et al.   CANCER LETTERS

Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cells

(2012) S. Mazumder et al.   CANCER RESEARCH

Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice

(2012) P N Kelly et al.   CELL DEATH AND DIFFERENTIATION

Targeting the Bcl-2 family for cancer therapy

(2012) Shibu Thomas et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Artemin Stimulates Radio- and Chemo-resistance by Promoting TWIST1-BCL-2-dependent Cancer Stem Cell-like Behavior in Mammary Carcinoma Cells

(2012) Arindam Banerjee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Silencing disease genes in the laboratory and the clinic

(2011) Jonathan K Watts et al.   JOURNAL OF PATHOLOGY

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure

(2010) Yasukazu Sagawa et al.   TUMOR BIOLOGY

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status

(2009) Ayad M Al-Katib et al.   Journal of Hematology & Oncology

Bcl-2-family proteins and hematologic malignancies: history and future prospects

(2008) J. C. Reed   BLOOD

Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

(2008) Barbara Pro et al.   BRITISH JOURNAL OF HAEMATOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction

(2008) Michael D Wendt   Expert Opinion on Drug Discovery

Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model

(2008) Alan A Arnold et al.   Molecular Cancer

Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor- B, p53, bax, and p27 levels

(2008) C. A. Tucker et al.   MOLECULAR CANCER THERAPEUTICS

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

(2008) Scott Ackler et al.   MOLECULAR CANCER THERAPEUTICS

How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

(2008) Jerry E. Chipuk et al.   TRENDS IN CELL BIOLOGY